Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020–2022)
Authors:
- José Diogo R. SouzaJSJosé Diogo R. Souza
- Julia Cozar PachecoJPJulia Cozar Pacheco
- Giordano Novak RossiGRGiordano Novak Rossi
- Bruno O. De-PauloBDBruno O. De-Paulo
- Antonio W. ZuardiAZAntonio W. Zuardi
- Francisco S. GuimarãesFGFrancisco S. Guimarães
- Jaime E. C. HallakJHJaime E. C. Hallak
- José Alexandre CrippaJCJosé Alexandre Crippa
- Rafael G. Dos SantosRafael G. Dos Santos
Open Access
- 25 November 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12) , 2598
Abstract
(1) Background: With the massive demand for the use and commercialization of medicinal cannabidiol (CBD) products, new randomized clinical trials (RCTs) are being published worldwide, with a constant need for safety and efficacy evaluation. (2) Methods: We performed an update on a systematic review published in 2020 that focused on analyzing the serious adverse effects (SAEs) of CBD in RCTs and its possible association with drug interactions. We also updated the report of the most prevalent CBD adverse effects (AEs). We systematically searched EMBASE, MEDLINE/PubMed, and Web of Science without language restriction for RCTs that reported adverse effects after repeated oral CBD administration for at least one week in healthy volunteers or clinical samples published from January 2019 to May 2022. The included studies were assessed for methodological quality by the Quality Assessment of Controlled Intervention Studies tool. The present review is registered on PROSPERO, number CRD42022334399. (3) Results: Twelve studies involving 745 randomized subjects analyzed were included (range 1.1–56.8 y). A total of 454 participants used CBD in the trials. The most common AEs of CBD were mild or moderate and included gastrointestinal symptoms (59.5%), somnolence (16.7%), loss of appetite (16.5%), and hypertransaminasemia (ALT/AST) (12.8%). Serious adverse effects include mainly hypertransaminasemia with serum levels elevations greater than three times the upper limit of the normal (6.4%), seizures (1.3%), and rash (1.1%). All SAEs reported in the studies were observed on CBD as an add-on therapy to anticonvulsant medications, including clobazam and valproate. (4) Conclusion: Recent RCTs involving oral CBD administration for at least a week suggest that CBD has a good safety and tolerability profile, confirming previous data. However, it can potentially interact with other drugs and its use should be monitored, especially at the beginning of treatment.Keywords
This publication has 28 references indexed in Scilit:
- A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with EpilepsyCNS Drugs, 2020
- Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trialsExpert Opinion on Drug Metabolism & Toxicology, 2020
- Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trialsNeuropsychopharmacology, 2020
- Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosisPsychopharmacology, 2020
- The therapeutic role of Cannabidiol in mental health: a systematic reviewJournal of Cannabis Research, 2020
- A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy SubjectsClinical Pharmacology in Drug Development, 2019
- Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New AgeFrontiers in Immunology, 2018
- Cannabinoids and Cytochrome P450 InteractionsCurrent Drug Metabolism, 2016
- Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomesLife Sciences, 2011
- Cannabinoids and the gastrointestinal tractGut, 2001